



Eversense[®] CGM System

The world's **FIRST** and **ONLY** long-term Continuous Glucose Monitoring System

Tim Goodnow
President and Chief Executive Officer

Corporate Presentation
May 2024

FORWARD-LOOKING STATEMENTS

Any statements in this presentation about future expectations, plans and prospects for Senseonics and its business, including statements regarding managements plans, objectives and goals for future operations, expectations for future financial or other performance, statements about the commercial launch and growth of Eversense® E3 and Eversense RPM programs, statements regarding progress and timing of collaboration and adoption or growth with respect to Eversense and any health system, or its patients and providers, or the potential to enhance patient outcomes or reduce healthcare costs or other benefits, statements regarding increasing patient access, adoption and market share and the future growth of the CGM market, statements regarding advancing development programs and potential regulatory filings, statements regarding future marketing programs or investment by Senseonics or its partners, and other statements containing the words “believe,” “expect,” “intend,” “may,” “projects,” “will,” “planned,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations and projections about future events, and such statements are, by their nature subject to uncertainties. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the ongoing commercialization of the Eversense product and the expansion of the Eversense product and a new RPM solution, uncertainties inherent in the transition of commercialization responsibilities to Ascensia Diabetes Care and its commercial initiatives, uncertainties inherent in finalizing integration and commercial terms with new partners or other third parties, uncertainties in user decisions and responses to new technology or initiatives, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties inherent in the development and registration of new technology, uncertainties relating to the current economic environment, uncertainties in the development of the overall CGM market, and such other factors as are set forth in the risk factors detailed in Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2023 and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, each as filed with the SEC, and Senseonics’ other filings with the SEC under the heading “Risk Factors.” In addition, the forward-looking statements included in this presentation represent Senseonics’ views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics’ views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. This presentation also presents management’s goals and vision for Senseonics development programs, including without limitation the Gemini and Freedom development programs. These products are not approved by the FDA and are not subject to an IDE or other investigational approval. Plans, timing, specifications and other details of these programs are subject to change based on the factors above. The forward-looking statements in this presentation should not be relied upon as representing Senseonics’ views as of any date subsequent to the date hereof.


OUR MISSION

To transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology.



CORPORATE OVERVIEW AND MILESTONES


The **FIRST** and **ONLY** long-term and implantable CGM System. Available by prescription in US and select markets in Europe. Proven technology with rich development history, regulatory approvals and commercial accomplishments.



NOTE: Items in blue are based on a number of risks and assumptions.

HIGH GROWTH MARKET

CGM Fastest Growing Diabetes Technology Segment Globally*




\$20B+
Annual US
Total
Addressable
Market
Opportunity**

*Estimates for top 4 CGM companies (Dexcom, Abbott, Medtronic and Senseonics), based upon available publicly stated guidance, historic performance, and external CGM market models & Company reports, company and analyst estimates.

**Estimated total U.S. market opportunity based on total number of U.S. people with diabetes diagnoses for which CGM is covered

US CGM MARKET REMAINS UNDERPENETRATED


Market Size (Patient Population)




*Senseonics Estimates

SIGNIFICANT UNMET NEED AMONG BGM/CGM USERS

★ Why BGM users won't adopt CGM¹



★ Most desired CGM improvements²



¹ Market Segmentation Research June 2019

² dQ&A CGM US Patient Survey Q3 2022

Eversense CGM System addresses unmet needs as

THE **FIRST** AND ONLY

- CGM that lasts for 6 months vs. days
- Fully implantable 3rd generation sensor
- CGM achieves 8.5% MARD*
- Transmitter that is removable
- System with on-body vibrate alerts for hypo and hyper warnings
- System with fresh, gentle-on skin adhesive patch
- Device that does not require self-insertions
- Sensor that has approved MRI conditional labeling

Therapeutic indication for 18 yo and older.

*Eversense E3 CGM System includes the Eversense E3 Sensor where sacrificial boronic acid (SBA) design modification was incorporated. In the PROMISE study, MARD of 8.5% was observed in the E3 Sensor, and MARD of 9.1% was observed in primary Sensor (which did not have SBA design modification).



Sensor



Smart Transmitter



Mobile App

Eversense CGM+RPM Solution

INTEGRATE THE EVERENSE CGM SYSTEM WITH REMOTE PATIENT MONITORING TECHNOLOGY TO ENABLE REAL-TIME HEALTH TRACKING AND PROVIDE PROACTIVE MANAGEMENT

Facilitating systemic at-risk patient management between office visits



Goals:



Competitive Differentiator

Providing a comprehensive solution for patients, providers and healthcare systems



Improves Clinical Outcomes

Offering lifestyle and therapy optimization in between office visits




Reduces Cost of Care

Reduce ER visits and acute care frequency


EVERSENSE US PATIENT PROFILES¹

Broad appeal of Eversense with new and existing CGM users


Over 2/3 of our US patients switched from other CGM solutions²



Usage split evenly across age groups



New Users by Diabetes Type



Target patient profiles

- Dissatisfied with Current CGM
- New to CGM
- Gateway (Libre)

Top preferred features of existing users

- Accuracy
- Sensor Life
- Implantable Convenience

¹ Senseonics Analysis
² Ascensia internal data

STRONG AND EXPANDING REIMBURSEMENT

ACCESS FOR OVER 300 MILLION LIVES

Recent Local Coverage Determinations from Medicare Administrative Contractors extends coverage to **all individuals with diabetes who use insulin** and non-insulin-taking patients **at risk of hypoglycemia**. Effectively **doubling** the total addressable patient population

Strong adoption of **180-day payment** across commercial payers

CMS Calendar Year 2023 Medicare Physician Fee Schedule initiated updates to **national pricing** that accounts for the longer 6-month sensor for all three CPT codes used for the Eversense E3 system



COMMERCIAL COLLABORATION WITH ASCENSIA

- Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in BGM
- ASCENSIA is the Exclusive Worldwide Distribution Partner for Eversense® E3 and Future Generation Products
- Senseonics to Focus Streamlined Operations on Manufacturing, Research and Development of Next Generations of Eversense® Systems
- Revenue sharing arrangement - Ascensia's share of revenue increases with volume and contract duration

Leverage ADC commercial strength with current and new products



Eversense E3 CGM



- A leader in BGM with 80 YEARS of innovative diabetes care products
- Approximately \$1B in sales in over 125 countries and covering 10 million people
- Approximately 1700 employees working in 31 countries

Focus Areas:

- Focus in select markets with reimbursement
- Build brand awareness and adoption
- Protect and grow installed base

2022 – 2025*
WW Annual Commercial Investment:
≈ \$30M to \$80M per year

*Current investment and headcount plans with ADC. Subject to change.

COMPREHENSIVE COMMERCIAL STRATEGY

FOCUS ON INCREASING AWARENESS AND ACCESS TO EVERSENSE



ADC's Dedicated CGM Unit

Newly formed unit with independent resources to drive Eversense expansion

Led by industry veteran Brian Hansen (former CCO of Tandem)



Prescribers and Inserters

US: ~800 certified inserters and 3,000 prescribers (endo + primary care)

OUS: 1,000+ inserters



Inserter Network

Augmented by ~35 geographies covered by NPG's certified inserters


Network of 10,000+ healthcare professionals

HEALTH SYSTEM SOLUTION WITH MERCY



- **Top 20 largest US health system** 3 million served
- **~30,000 patients** in need of **CGM**
- **Top 10** most successful **ACO**
- One of **America's Most Innovative** companies by Fortune magazine
- **19 time** winner of **"Most Wired"** health systems award

- Developing multi-year collaboration
- Eversense CGM™, advanced analytics, AI, and Eversense RPM™
- Systemic monitoring of patients at risk
- Controlled launch targeted beginning July 2024



The CGM for Real Life

COMPREHENSIVE DIRECT TO CONSUMER MARKETING CAMPAIGN TO BUILD AWARENESS

Increased leads by 3x in 4Q23

Linear TV



Testing on traditional broadcast television in **5** metropolitan markets

Connected TV



Digital television platforms such as YouTube, Hulu, HBO, and Disney+

Paid Social Media



Targeted advertising on Instagram, TikTok, YouTube, and LinkedIn



EVERSENSE PIPELINE

PRODUCT VISION

Uniquely differentiated long-term technology solution with multiple product configurations with AID and Smart Pen integration

1 SENSOR

All Diabetes Patient Segments

NO sensor change for 1 year

NO daily calibration required

NO transmitter on body

Product development timelines and specifications subject to risks and uncertainties.



For Type 1 and Type 2 Patients
On Demand and Continuous Monitoring


PORTFOLIO OVERVIEW

Connectivity Updates

BGM Connectivity
Direct communication with Bluetooth enabled blood glucose meters

Pump Integration
Sensor augments pump

Pump AID
CGM controls pump



Product development timelines and specifications subject to risks and uncertainties.

GEMINI SYSTEM

Autonomous sensor testing with data processing capacity enabling 2 products from 1 platform

TECHNOLOGY


Enhanced ROME2 sensor with integrated battery; updated algorithm

USE CASE

Full year use with 1 sensor and 1 cal/week

Two unique products:

- **CGM with transmitter**



- **Standalone therapeutic FGM without transmitter**



TARGET

Intensively managed patients who want better control


+ **All insulin-using patients**

+ **Non-insulin patients**

Product development timelines and specifications subject to risks and uncertainties.

FREEDOM SYSTEM

Elimination of Transmitter by incorporating BLE in the Sensor



TECHNOLOGY

Enhanced ROME2 sensor with integrated battery and **BLE communication**; updated algorithm

USE CASE

Full year use with 1 sensor and 1 cal/week

No transmitter included in the System

Direct communication between sensor and handheld

TARGET

Intensively managed patients who want better control

+ **All insulin-using patients**

+ **Non-insulin patients**

eversense
Continuous Glucose Monitoring System



**“ACCURATE.
CONVENIENT.
LIFE-CHANGING.”**

eversense
Continuous Glucose Monitoring System

A blue-tinted photograph of a man and a woman jogging on a path. The woman is on the left, wearing a dark tank top and light shorts, holding a leash for a small dog. The man is on the right, wearing a light t-shirt and dark shorts. The dog is running ahead of them. The background is a dense forest. The text "THANK YOU" is overlaid in white, bold, sans-serif font in the center of the image.

THANK YOU